Generated by AI
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and markets technically challenging generic and proprietary injectable, inhalation, and intranasal products. Amphastar Pharmaceuticals, Inc. also supplies active pharmaceutical ingredient products, including insulin APIs, supporting both its own finished medicines and external customers. Its portfolio includes prescription and over-the-counter treatments used in hospital, urgent care, and retail pharmacy settings, with products addressing areas such as respiratory care, allergic reactions, anticoagulation, opioid overdose reversal, and diagnostic support. The company operates through its Pharmaceutical Products segment and emphasizes complex drug delivery systems, biologics, and biosimilar capabilities. Amphastar Pharmaceuticals, Inc. serves healthcare providers, distributors, and patients across the United States and selected international markets.
Website11570 6th Street
Rancho Cucamonga, CA, 91730
United States
The latest articles about AMPH.
Amphastar Pharmaceuticals reported third quarter 2026 revenue of US$207.61 million and net income of US$37.76 million, with adjusted earnings per share and sales both coming in ahead of consensus expectations. Record contributions from BAQSIMI and Primatene Mist, together with expanded authorization for the share repurchase program, highlighted management’s focus on higher margin products and capital return. This article examines how Amphastar Pharmaceuticals’ investment narrative is...
Summary of Jun 5's posts. Generated by AI.
No summary yet.
Summary of Jun 5's posts. Generated by AI.
Summary of Mar 13's posts. Generated by AI.
Summary of Jun 5's posts. Generated by AI.
Investors talking about AMPH also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.